Trials / Unknown
UnknownNCT05776355
NKG2D CAR-NK & Ovarian Cancer
NKG2D CAR-NK Cell Therapy for Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Hangzhou Cheetah Cell Therapeutics Co., Ltd · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will explore the maximum tolerated dose （MTD）of NKG2D CAR-NK cells in the treatment of platinum-resistant, relapsed epithelial ovarian cancer in a dose-escalation manner, and observe the clinical safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NKG2D CAR-NK | Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2024-04-01
- Completion
- 2024-09-01
- First posted
- 2023-03-20
- Last updated
- 2023-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05776355. Inclusion in this directory is not an endorsement.